ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

COS Collagen Solutions Plc

6.625
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.625 6.25 7.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Collagen Solutions PLC ChondroMimetic® Update (5866O)

31/01/2019 7:00am

UK Regulatory


Collagen Solutions (LSE:COS)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Collagen Solutions Charts.

TIDMCOS

RNS Number : 5866O

Collagen Solutions PLC

31 January 2019

31 January 2019

Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")

ChondroMimetic(R) Update

Distribution Agreement with Indonesian Partner and Update on CE Mark Process

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a new license and distribution agreement for ChondroMimetic(R) with an Indonesian partner, PT Rajawali Mutiara Sejahtera ("Rajawali Medika"). Rajawali Medika will collaborate with Collagen Solutions to obtain regulatory approval and launch ChondroMimetic(R) in Indonesia with the potential to expand to several other South East Asian countries. Financial terms of the agreement were not disclosed.

Rajawali Medika, based in Jakarta, was founded and managed by highly experienced professionals in sales and marketing of medical devices in the Asia Pacific region. The team's prior experience includes successful hands-on sales and marketing of sports medicine and arthroscopy products with J&J's DePuy Mitek division. Rajawali Medika has a strong network of key orthopaedic surgeons and sales distribution channels in South East Asian countries, experience in conducting professional education programmes and workshops, as well as experience in regulatory affairs to achieve speed to market.

ChondroMimetic(R) is a minimally-invasive surgically placed scaffold for the repair of cartilage defects in the knee, backed by positive results of an eight-year clinical extension study reported in Q1 2018. The Company has made a submission for a CE Mark for ChondroMimetic(R) and is currently awaiting further feedback from the Notified Body reviewing the submission. The timing of the CE Mark approval is subject to a due process to be undertaken by the Regulatory Authority, and the previously stated timing of approval by the fiscal year end is therefore uncertain. ChondroMimetic(R) is not currently approved for sale in any markets.

Jamal Rushdy, CEO, commented: "We are pleased to enter the partnership agreement with Rajawali Medika for Chondromimetic in South East Asia. We will benefit enormously from both their in-depth expertise in the area of sports medicine procedures as well as their regional presence. This agreement adds to other distributor agreements that we have been putting in place in Asia and Europe in order to initiate our launch of Chondromimetic soon after we obtain regulatory approval. We are currently awaiting feedback regarding our CE Mark submission and we will provide an update once new information becomes available and certainly no later than our proposed April trading update."

Enquiries:

 
 Collagen Solutions Plc 
 Jamal Rushdy, CEO                                                     Via Walbrook 
 Hilary Spence, CFO 
 
 Cenkos Securities Plc (Nominated 
  Adviser and Broker) 
 Steve Cox (Corporate Finance)                                   Tel: 0207 397 8900 
 Giles Balleny 
 
 Walbrook PR Ltd                      Tel: 020 7933 8780 or collagen@walbrookpr.com 
 Anna Dunphy                                                     Mob: 07876 741 001 
 Helen Cresswell                                                 Mob: 07841 917 679 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDEAKFEDEKNEFF

(END) Dow Jones Newswires

January 31, 2019 02:00 ET (07:00 GMT)

1 Year Collagen Solutions Chart

1 Year Collagen Solutions Chart

1 Month Collagen Solutions Chart

1 Month Collagen Solutions Chart

Your Recent History

Delayed Upgrade Clock